Another Innovative Electrophysiology Ablation Catheter Receives NMPA Approval via Fast-Track Review

Mar 27, 2025 11:00 CST Updated 11:00

APT Medical

Cardiac Electrophysiology and Interventional Medical Device R&D Manufacturer

APT Medical

Minimally Invasive Cardiovascular and Cerebrovascular Interventional Device R&D, Manufacturer, and Distributor

Yesterday, NMPA announced the approval of an innovative product for marketing, which is from a subsidiary of APT Medical.APT Medical Inc.TheSingle-Use Pressure Monitoring RF Ablation Catheter。

The disposable pressure monitoring radiofrequency ablation catheter, composed of the distal end, tube body, handle, cable, saline connector, and photoelectric hybrid plug, is used in conjunction with the cardiac radiofrequency ablation instrument produced by Shanghai Hongtong Industrial Co., Ltd. (a subsidiary of APT Medical), mainly...For the treatment of drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation。

Innovation in Disposable Pressure Monitoring RF Ablation Catheter Technology:

The CatheterReal-time monitoring and feedback of pressure during clinical use is achieved through a built-in optical pressure sensor, ensuring the stability of the ablation effect.。This catheter can effectively reduce the risks of steam pop caused by excessive contact between the catheter and tissue during surgery or incomplete ablation due to insufficient contact, benefiting more patients with paroxysmal atrial fibrillation.

APT Medical is currently the best company in China's electrophysiology field (with a market value exceeding 36 billion yuan). Last year, its revenue reached 2.066 billion yuan, representing a year-on-year increase of 25.18%; the attributable net profit achieved was 673 million yuan, marking a year-on-year growth of 26.14%. The company has developed a complete solution in the electrophysiology field: it includes 3D mapping, mapping catheters, PFA products, and radiofrequency ablation products.

Previously, APT Medical broke the foreign monopoly in the electrophysiology field through technological innovation, gradually competing against Johnson & Johnson, Abbott, and others, while establishing a complete electrophysiology solution. Now, with the arrival of the PFA era, domestic and international companies are pulled back to the same starting line. Last yearAPT Medical's PFA product has also been approved for marketing by the NMPA. With previous market and technical accumulation, as well as subsequent centralized procurement policies, APT Medical is highly likely to gradually replace foreign giants and become the company with the largest market share in China.